Qualigen Therapeutics CEO Michael Poirier notified the board of directors on September 23 of his intention to resign as CEO and Chairman of the Board of the company, effective immediately. On the same date, CFO Christopher Lotz also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the company regarding its future direction and strategic initiatives. On September 25, the board of directors appointed Campbell Becher as President, effective immediately. On September 26, the board of directors appointed Kevin Richardson as Interim CEO and CFO as well as a member of the board of directors. Richardson most recently served as CEO of Sanuwave Health, a medical device startup.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QLGN: